Clinical trial · Observational
Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix
Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The DUO study's main objective is to evaluate, in the real life, the prevalence of cardiovascular risk in patients with prostate cancer that hormone treatment of androgen suppression by Degarelix was introduced. This study will also assess, at the initiation of therapy, the prevalence of osteoporosis, metabolic comorbidities, depression, sexual and geriatric patients suffering from prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Degarelix | Drug | Degarelix | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Degarelix
- interventionNames
- Drug: Degarelix
Primary outcomes (1)
- measure
- Occurrence of cardiovascular comorbidity
- timeFrame
- At inclusion
- description
- Measured by a history of at least one cardiovascular illness (according to ICD-10) and/or at least three cardiovascular risk factors (as defined by Cancer Committee of the French Urology Association)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male aged 18 years or older * Diagnosed with prostate cancer * Patient having received an antagonist of GnRH Degarelix prescription. * Agreeing to and capable of completing in French during the visits all questionnaires on the impact of their illness and treatment. * Patients having received oral and written study information, agreeing to the use of his anonymized data, and having signed a written Informed Consent Form. Exclusion Criteria: * Patient included in an interventional study assessing treatment for prostate cancer. * Patient presenting hypersensitivity to Degarelix or one of its excipients. * Patient treated by other hormonotherapy.
References
Publications (0)
Data not yet available